Literature DB >> 14679302

Defining a metabolic phenotype in the brain of a transgenic mouse model of spinocerebellar ataxia 3.

J L Griffin1, C K Cemal, M A Pook.   

Abstract

Many of the spinocerebellar ataxias (SCAs) are caused by expansions of CAG trinucleotide repeats encoding abnormal stretches of polyglutamine. SCA3 or Machado-Joseph disease (MJD) is the commonest dominant inherited ataxia disease, with pathological phenotypes apparent with a CAG triplet repeat length of 61-84. In this study a mouse model of SCA3 has been examined which was produced using a human yeast artificial chromosome containing the MJD gene with a CAG triplet expansion of 84 repeats. These mice have previously been shown to possess a mild progressive cerebellar deficit. NMR-based metabolomics/metabonomics in conjunction with multivariate pattern recognition identified a number of metabolic perturbations in SCA3 mice. These changes included a consistent increase in glutamine concentration in tissue extracts of the cerebellum and cerebrum and spectra obtained from intact tissue using magic angle spinning (1)H-NMR spectroscopy. Furthermore, these profiles demonstrated metabolic abnormalities were present in the cerebrum, a region not previously implicated in SCA3. As well as an increase in glutamine both brain regions demonstrated decreases in GABA, choline, phosphocholine and lactate (representing the summation of lactate in vivo, and postmortem glycolysis of glucose and glycogen). The metabolic changes are discussed in terms of the formation of neuronal intranuclear inclusions associated with SCA3. This study suggests high-resolution (1)H-NMR spectroscopy coupled with pattern recognition may provide a rapid method for assessing the phenotype of animal models of human disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14679302     DOI: 10.1152/physiolgenomics.00149.2003

Source DB:  PubMed          Journal:  Physiol Genomics        ISSN: 1094-8341            Impact factor:   3.107


  14 in total

Review 1.  The application of NMR-based metabonomics in neurological disorders.

Authors:  Elaine Holmes; Tsz M Tsang; Sarah J Tabrizi
Journal:  NeuroRx       Date:  2006-07

Review 2.  The Cinderella story of metabolic profiling: does metabolomics get to go to the functional genomics ball?

Authors:  Julian L Griffin
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2006-01-29       Impact factor: 6.237

Review 3.  Genetically engineered mouse models of the trinucleotide-repeat spinocerebellar ataxias.

Authors:  Melissa A C Ingram; Harry T Orr; H Brent Clark
Journal:  Brain Res Bull       Date:  2011-07-23       Impact factor: 4.077

4.  In Vivo Molecular Signatures of Cerebellar Pathology in Spinocerebellar Ataxia Type 3.

Authors:  Maria do Carmo Costa; Maria Radzwion; Hayley S McLoughlin; Naila S Ashraf; Svetlana Fischer; Vikram G Shakkottai; Patrícia Maciel; Henry L Paulson; Gülin Öz
Journal:  Mov Disord       Date:  2020-07-04       Impact factor: 10.338

5.  Targeted metabolomics.

Authors:  Lee D Roberts; Amanda L Souza; Robert E Gerszten; Clary B Clish
Journal:  Curr Protoc Mol Biol       Date:  2012-04

Review 6.  Mouse models of spinocerebellar ataxia type 3 (Machado-Joseph disease).

Authors:  Veronica F Colomer Gould
Journal:  Neurotherapeutics       Date:  2012-04       Impact factor: 7.620

Review 7.  Metabolic Profiling and Phenotyping of Central Nervous System Diseases: Metabolites Bring Insights into Brain Dysfunctions.

Authors:  Marc-Emmanuel Dumas; Laetitia Davidovic
Journal:  J Neuroimmune Pharmacol       Date:  2015-01-24       Impact factor: 4.147

8.  1H NMR-based metabolomics investigation of copper-laden rat: a model of Wilson's disease.

Authors:  Jingjing Xu; Huaizhou Jiang; Jinquan Li; Kian-Kai Cheng; Jiyang Dong; Zhong Chen
Journal:  PLoS One       Date:  2015-04-07       Impact factor: 3.240

9.  Metabolic phenotyping and systems biology approaches to understanding neurological disorders.

Authors:  Marc-Emmanuel Dumas; Laetitia Davidovic
Journal:  F1000Prime Rep       Date:  2013-06-03

Review 10.  Mouse models of polyglutamine diseases: review and data table. Part I.

Authors:  Maciej Figiel; Wojciech J Szlachcic; Pawel M Switonski; Agnieszka Gabka; Wlodzimierz J Krzyzosiak
Journal:  Mol Neurobiol       Date:  2012-09-07       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.